ClinicalTrials.gg

Program

L-(+)-methylenetetrahydrofolic acid

Also written as “Arfolitixorin”, “Modufolin (arfolitixorin)” and “6R-MTHF (arfolitixorin) 200 mg/m2”.

Its studies are mostly in Colorectal Neoplasms · Colonic Neoplasms, led by Isofol Medical AB.

Furthest: phase 3, since Nov 19, 20185 company-led studies, 1 open or runningNext primary completion: Nov 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Isofol Medical AB51 open or runningphase 3since Nov 19, 2018Sep 5, 2012Nov 30, 2028phase 2 · NCT06922383

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2012First study: phase 2 study in Colonic NeoplasmsFirst studyNCT01681472 · 32 enrolled · Sweden
  2. Sep 17, 2014Phase 2 study in Colorectal NeoplasmsNCT02244632 · 105 enrolled · Denmark, Greece, Norway and more
  3. Jun 22, 2017Phase 1 study in Phase I Study in Healthy Volunteers to Evaluate ECG EffectNCT03203564 · 33 enrolled · Sweden
  4. Nov 19, 2018Phase 3 study in Colonic NeoplasmsNCT03750786 · 490 enrolled · United States, Australia, Austria and more
  5. Mar 25, 2025Phase 2 study in Colorectal NeoplasmsNCT06922383 · 90 planned · Germany

Ahead

  1. Nov 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06922383

TargetBeta

HTT →read by rule
“The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect agai”NCIt, by rule

Other programs on HTT

ProgramCompanyFurthest phaseStudies
votoplamNovartisphase 33
SKY-0515ruleskyhawk-therapeutics-incphase 32

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06922383Colorectal Neoplasms · Germany2RecruitingNov 30, 202890
NCT03750786Colonic Neoplasms · United States, Australia, Austria and more3CompletedNov 18, 2022490
NCT03203564Phase I Study in Healthy Volunteers to Evaluate ECG Effect · Sweden1CompletedAug 25, 201733
NCT02244632Colorectal Neoplasms · Denmark, Greece, Norway and more2CompletedJan 30, 2020105
NCT01681472Colonic Neoplasms · Sweden2CompletedAug 201332

How it is read

Names in the registry

  • “Arfolitixorin”, 2 entries
  • “Modufolin (arfolitixorin)”, 2 entries
  • “6R-MTHF (arfolitixorin) 200 mg/m2”, 1 entry
  • “6R-MTHF (arfolitixorin) 60 mg/m2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.